Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
Healthcare
$17.22 +3.01%
+$0.81 today
- Market cap
- $1.76B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
52W Low $18.29High $42.37
Volume 3.12M
Average 1.81M
Income Statement
Follow revenue through to earnings.
Revenue
$673.00M
FY 2025 · Annual
+20.1% YoYOperating Income
-$535.00M
FY 2025 · Annual
Net Income
-$575.00M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.41M | 363.33M | 434.25M | 560.23M | 673M |
| Cost of Revenue | 16.01M | 28.32M | 45.21M | 76.73M | 109M |
| Gross Profit | 335.4M | 335.01M | 389.04M | 483.5M | 564M |
| Gross Margin | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| Research & Development | 497.15M | 705.79M | 648.45M | 697.87M | 750M |
| Selling, General & Admin | 219.98M | 278.14M | 309.8M | 321.61M | 349M |
| Operating Expenses | 717.14M | 983.93M | 958.25M | 1.02B | 1.1B |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| EBITDA | (410.32M) | (640.49M) | (516.45M) | (469M) | (474M) |
| EBITDA Margin | -116.8% | -176.3% | -118.9% | -83.7% | -70.4% |
| Operating Income | (381.74M) | (648.92M) | (569.21M) | (535.97M) | (535M) |
| Operating Margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Interest Income | 1.93M | 11.07M | 26.69M | 36.51M | 25M |
| Interest Expense | 29.42M | 43.02M | 66M | 63.04M | 62M |
| Other Income / Expenses | (71.24M) | (52.81M) | (39.26M) | (31.61M) | (36M) |
| Income Before Tax | (452.98M) | (701.73M) | (608.46M) | (567.59M) | (571M) |
| Pre-Tax Margin | -128.9% | -193.1% | -140.1% | -101.3% | -84.8% |
| Income Tax Expense | 1.04M | 5.7M | (1.83M) | 1.6M | 4M |
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Net Margin | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |
| EPS (Basic) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| EPS (Diluted) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| 67.8M | 69.91M | 73.54M | 90.54M | 98.6M | |
| 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
RARE Earnings Waterfall · TTM
NASDAQ:RARE · Revenue to Net Income
Key Ratios
EPS$-6.11
Gross Margin83.2%
Net Margin-95.0%
P/E Ratio-4.8
P/S Ratio16.7
Analysis
$669.4M of revenue converted into -$609.4M of net income for the selected period. Gross margin is 83.2% and net margin is -95.0%, showing how much revenue survives after costs and taxes. EPS is $-6.11, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 30, 2026 |
How much revenue does RARE generate?
Ultragenyx Pharmaceutical Inc. (RARE) reported $673.00M of revenue in fiscal 2025.
Is RARE profitable?
Ultragenyx Pharmaceutical Inc. (RARE) reported -$575.00M of net income, with a net margin of -85.4%.
Continue the stock analysis
Jump to another research area for this company.